AU9167798A - Use of at least an extract of the genus chrysanthemum for assisting skin and/or hair pigmentation - Google Patents
Use of at least an extract of the genus chrysanthemum for assisting skin and/or hair pigmentation Download PDFInfo
- Publication number
- AU9167798A AU9167798A AU91677/98A AU9167798A AU9167798A AU 9167798 A AU9167798 A AU 9167798A AU 91677/98 A AU91677/98 A AU 91677/98A AU 9167798 A AU9167798 A AU 9167798A AU 9167798 A AU9167798 A AU 9167798A
- Authority
- AU
- Australia
- Prior art keywords
- chrysanthemum
- plant
- extract
- composition
- genus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 235000007516 Chrysanthemum Nutrition 0.000 title claims abstract description 31
- 244000189548 Chrysanthemum x morifolium Species 0.000 title claims description 38
- 230000003793 hair pigmentation Effects 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 241000196324 Embryophyta Species 0.000 claims abstract description 44
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 210000004209 hair Anatomy 0.000 claims description 27
- 230000019612 pigmentation Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000003061 melanogenesis Effects 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 7
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 239000003908 antipruritic agent Substances 0.000 claims description 4
- 239000000058 anti acne agent Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000002141 anti-parasite Effects 0.000 claims description 3
- 230000001139 anti-pruritic effect Effects 0.000 claims description 3
- 229940124340 antiacne agent Drugs 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 235000007871 Chrysanthemum coronarium Nutrition 0.000 claims description 2
- 244000067456 Chrysanthemum coronarium Species 0.000 claims description 2
- 240000005250 Chrysanthemum indicum Species 0.000 claims description 2
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims description 2
- 235000005470 Chrysanthemum segetum Nutrition 0.000 claims description 2
- 244000144786 Chrysanthemum segetum Species 0.000 claims description 2
- 229940124091 Keratolytic Drugs 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 230000001530 keratinolytic effect Effects 0.000 claims description 2
- 241000404070 Coleostephus myconis Species 0.000 claims 1
- 239000000419 plant extract Substances 0.000 abstract description 5
- 241000723353 Chrysanthemum Species 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 23
- 239000006210 lotion Substances 0.000 description 19
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 208000012641 Pigmentation disease Diseases 0.000 description 11
- 210000002752 melanocyte Anatomy 0.000 description 11
- 239000006071 cream Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 210000002780 melanosome Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 4
- 229950000329 thiouracil Drugs 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007957 coemulsifier Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229950001046 piroctone Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LHENQXAPVKABON-UHFFFAOYSA-N 1-methoxypropan-1-ol Chemical compound CCC(O)OC LHENQXAPVKABON-UHFFFAOYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- OQZGLXOADHKTDN-UHFFFAOYSA-N 1-oxidopyrimidin-1-ium Chemical class [O-][N+]1=CC=CN=C1 OQZGLXOADHKTDN-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- CSWRIBMIYCFPFK-UHFFFAOYSA-N 4-n,4-n-dimethyl-6-n-propylpyrimidine-2,4,6-triamine Chemical compound CCCNC1=CC(N(C)C)=NC(N)=N1 CSWRIBMIYCFPFK-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000208837 Asterales Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OBLBZOYQSFBPED-UHFFFAOYSA-N CCCNC1=CC(N(C)C)=NC(NCCC)=[N+]1[O-] Chemical compound CCCNC1=CC(N(C)C)=NC(NCCC)=[N+]1[O-] OBLBZOYQSFBPED-UHFFFAOYSA-N 0.000 description 1
- RYRUMTRRYBKFLK-UHFFFAOYSA-N CCCNC1=[N+]([O-])C(NCCC)=CC(N2CCCCC2)=N1 Chemical compound CCCNC1=[N+]([O-])C(NCCC)=CC(N2CCCCC2)=N1 RYRUMTRRYBKFLK-UHFFFAOYSA-N 0.000 description 1
- ASHRKMNTIDVPMJ-UHFFFAOYSA-N CCNC1=CC(N(C)C)=NC(NCC)=[N+]1[O-] Chemical compound CCNC1=CC(N(C)C)=NC(NCC)=[N+]1[O-] ASHRKMNTIDVPMJ-UHFFFAOYSA-N 0.000 description 1
- LIMVNCBWAMZOGT-UHFFFAOYSA-N CNC1=CC(N(C)C)=NC(NC)=[N+]1[O-] Chemical compound CNC1=CC(N(C)C)=NC(NC)=[N+]1[O-] LIMVNCBWAMZOGT-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- OXBWMYPHATXJIX-UHFFFAOYSA-N NC1=[N+]([O-])C(NC)=CC(N2CCCCC2)=N1 Chemical compound NC1=[N+]([O-])C(NC)=CC(N2CCCCC2)=N1 OXBWMYPHATXJIX-UHFFFAOYSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 241000863026 Vitreoscilla filiformis Species 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical class [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940073642 ceteareth-30 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000481 effect on pigmentation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940119519 peg-32 stearate Drugs 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 150000003180 prostaglandins Chemical group 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- QKHBMQWPOUUMQZ-BDQAORGHSA-M sodium;hydron;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC([O-])=O QKHBMQWPOUUMQZ-BDQAORGHSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960002304 thenalidine Drugs 0.000 description 1
- KLOHYVOVXOUKQI-UHFFFAOYSA-N thenalidine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CS1 KLOHYVOVXOUKQI-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention concerns the use in a cosmetic composition or for preparing a pharmaceutical composition of at least a plant extract of the genus Chrysanthemum for stimulating skin and/or hair pigmentation. The invention also concerns a composition containing at least one active principle and an extract of at least a plant of the genus Chrysanthemum.
Description
WO 99/13856 - 1 - PCT/FR98/01958 USE OF AT LEAST ONE EXTRACT OF THE GENUS CHRYSANTHEMUM FOR ASSISTING SKIN AND/OR HAIR PIGMENTATION The invention relates to the use of at least one extract of at least one plant of the genus 5 Chrysanthemum in a composition for assisting skin and/or hair pigmentation. The colour of the human hair and skin is a function of different factors and especially of the seasons of the year, the race, the sex and the age. It 10 is principally determined by the concentration in the keratinocytes of the melanin produced by the melanocytes. The melanocytes are the specialized cells which synthesize melanin through particular organelles, the melanosomes. 15 The synthesis of melanin or melanogenesis is particularly complex and schematically involves the following principal steps: tyrosine -+ dopa -+ dopaquinone -* dopachrome -+ melanin Tyrosinase (monophenol dihydroxyl 20 phenylalanine: oxygen oxidoreductase/EC 1,14,18,1) is the essential enzyme intervening in this sequence of reactions. It especially catalyses the conversion reaction of tyrosine into dopa (dihydroxyphenylalanine) and the conversion reaction of dopa into dopaquinone. 25 In the epidermis, the melanocyte is involved in the epidermal melanin unit which contains a melanocyte surrounded by approximately 36 neighbouring -1 P )44/44 WO 99/13856 - 2 - PCT/FR98/01958 keratinocytes. All individuals, without distinction of phototype, have approximately the same number of melanocytes for a given cutaneous zone. The ethnic differences, in terms of pigmentation, are not due to 5 the number of melanocytes, but to the properties of their melanosomes. The melanosomes are aggregated into complexes and are of small size. These are highly specialized organelles whose unique function is the production of melanin. They originate from the 10 endoplasmic reticulum in the form of spherical vacuoles called premelanosomes. The premelanosomes contain an amorphous protein substrate, but no melanogenic enzymes. In the course of maturation of the premelanosome, the amorphous substrate organizes into a 15 fibrillar structure orientated in the longitudinal axis of the melanosome. Four stages of development of the melanosome are distinguished corresponding to the intensity of melanization. Melanin is deposited uniformly on the internal fibrillar network of the 20 melanosome and the opacity of the organelle increases up to saturation. As the melanin is synthesized in the melanosomes, these move from the perinuclear region towards the end of the dendrites of the melanocytes. By phagocytosis, the end of the dendrites is captured by 25 the keratinocytes, the membranes are degraded and the melanosomes are redistributed in the keratinocytes. 1 WO 99/13856 - 3 - PCT/FR98/01958 Although the level of melanin varies from one population to another, the quantity of tyrosinase does not vary significantly and the level of messenger RNAs of the tyrosinase is identical in white or black skins. 5 The variations in melanogenesis are therefore due to variations either in the activity of the tyrosinase or in the capacity of the keratinocytes to phagocytose the melanosomes. It is known that in the majority of 10 populations the brown colour of the skin and the preservation of a constant coloration of the hair are important aspirations. In addition, pigmentation diseases exist such as, for example, vitiligo, which is an auto-immune 15 disease which is characterized by the appearance of white patches on the skin linked to a pigmentation defect. There is therefore a real need for a product facilitating and/or improving the pigmentation of the 20 skin and/or the hair. Numerous solutions have been proposed in the field of artificial coloration by supply of sensible exogenous colorants to give to the skin and/or the hair a coloration which is the closest possible to that 25 which is naturally or, in the field of natural coloration, by stimulation of the natural routes of pigmentation. 41 Cx WO 99/13856 - 4 - PCT/FR98/01958 For example, in the documents WO-A-9517161, WO-A-9511003, WO-A-9501773, WO-A-9404674, WO-A-9404122, EP-A-585018, WO-A-9310804, WO-A-9220322 or WO-A-9107945 solutions have been proposed which are as varied as 5 compositions containing a phosphodiesterase inhibitor, the use of prostaglandins, DNA fragments or even tyrosine derivatives. Excellent results are admittedly obtained by the solutions proposed in the prior art, but the 10 compounds used often have non-negligible side effects or are complex mixtures which do not have any specificity. The discovery of substances having an effect on pigmentation of the skin and/or the hair without having 15 inconvenient side effects remains a major research objective. The applicant has now discovered that at least one extract of at least one plant of the genus Chrysanthemum has an activatory effect on 20 melanogenesis. The plants of the genus Chrysanthemum are used in the prior art in compositions having depigmenting properties (JP07025745, JP07025746), compositions favouring the growth of the hair and/or 25 combating hair loss (FR2659014, EP569667, DE4330597, DE4312109, JP8081336, JP84154598, JP02048514), anti-dandruff compositions (KR9006824, JP62153211) or )41 WO 99/13856 - 5 - PCT/FR98/01958 compositions for maintaining the suppleness, the hydration and the sheen of the skin (JP62048611). The patent applications CN1094278 and CN1094279 relate to compositions for natural hair treatment. These 5 compositions have a variety of properties (embellishment of the hair, fixing, promotion of the blood circulation and the growth of the hair, bactericidal, anti-pruritic, anti-dandruff) among which an anti-white-hair action is mentioned. These 10 compositions are in fact a mixture of 2 components each formed of extracts of at least 9 plants, without it being possible to attribute one of the numerous properties cited to one more than another. To the knowledge of the applicant, use as an 15 active principle of a plant extract of the genus Chrysanthemum has never been claimed for assisting the pigmentation of the skin and/or the hair. The invention therefore relates to the use in a cosmetic composition or for the preparation of a 20 pharmaceutical composition, as active principle, of a sufficient quantity of at least one extract of at least one plant of the genus Chrysanthemum, this extract or the composition being intended to increase the pigmentation of the skin and/or of the hair. 25 The invention likewise relates to the use in a cosmetic composition or for the preparation of a pharmaceutical composition, as active principle, of a WO 99/13856 - 6 - PCT/FR98/01958 sufficient quantity of at least one extract of at least one plant of the genus Chrysanthemum for assisting melanogenesis. The extract of at least one plant of the 5 genus Chrysanthemum can be any extract prepared from any plant material originating from a plant of the genus Chrysanthemum. The composition can contain at least one extract of at least one plant of the genus Chrysanthemum obtained 10 from material originating from a plant cultivated in vivo or originating from in vitro culture. In vivo cultivation is understood as meaning any cultivation of conventional type, that is to say in soil in the open air or in a greenhouse, or 15 alternatively outside the soil. It is thus possible to use, for example, according to the invention an extract of different parts of the plant, leaves, flowers, stems, roots, undifferentiated cells, alone or as a mixture, whether 20 the plant is cultivated in vivo or in vitro. The selection pressure imposed by the physicochemical conditions during the growth of the plant cells in vitro allows a plant material to be obtained which is standardized and available throughout 25 the year unlike the plant cultivated in vivo. In vitro culture is understood as meaning all of the techniques known to the person skilled in the r-44 WO 99/13856 - 7 - PCT/FR98/01958 art which artificially allow the obtainment of a plant or of a part of a plant. Preferably, an extract obtained from plant material cultivated in vivo is used and even more 5 preferentially an extract obtained from leaves of plants of the genus Chrysanthemum cultivated in vivo. The genus Chrysanthemum belongs to the family of Compositae which itself belongs to the order of Asteracae (or Asterales). 10 The genus Chrysanthemum contains approximately 200 species native to Europe and Asia, amongst which it is possible to mention Chrysanthemum hortorum, Chrysanthemum morifolium, Chrysanthemum coronarium, Chrysanthemum mycon is, Chrysanthemum sagi tum, 15 Chrysanthemum indicum, or alternatively Chrysanthemum segetum Preferentially, according to the invention a plant is used originating from the species Chrysanthemum mori fol i um. 20 The species Chrysanthemum morifolium comprises numerous varieties amongst which it is possible to mention the variety sinense, preferentially used according to the invention. Extract of at least one plant of the genus 25 Chrysanthemum is understood as meaning both a crude mixture of parts of the plant coarsely reduced to pieces and of the extraction solvent as well as RIl
$V
WO 99/13856 - 8 - PCT/FR98/01958 preparations elaborated from the solubilized active principles during extraction. An extract which is particularly utilizable according to the invention is produced by the fine grinding of parts of the plant 5 followed by maceration in the extraction solvent and finally filtration. Quite obviously, the extract according to the invention can be each of the extracts thus obtained used on its own or as a mixture with one or more of the other extracts. 10 Any method of extraction known to the person skilled in the art can be used according to the invention. It is possible to mention, in particular, aqueous and alcoholic, especially ethanolic, extracts, and aqueous 15 alcoholic extracts. Whatever the form of the extract which it is intended to use, the techniques used to obtain it are those generally described in the prior art and well known to the person skilled in the art. 20 It is likewise possible to use an extract prepared by the method described in the French Patent Application No. 95-02379. Thus, in a first step the plant material is ground in a cold aqueous solution, in a second step the 25 particles in suspension are eliminated from the aqueous solution originating from the first step, and in a third step the aqueous solution originating from the
RI
WO 99/13856 - 9 - PCT/FR98/01958 second step is sterilized. This aqueous solution corresponds to the extract. On the other hand, the first step can advantageously be replaced by a simple freezing operation of the plant 5 tissues (for example at -200C), followed by an aqueous extraction taking over the second and third steps described above. Whatever the mode of preparation used according to the invention, subsequent steps aiming at 10 assisting preservation and/or stabilization can be added without for all that modifying the actual nature of the extract. Thus, for example, the extract obtained can be lyophilized by any conventional lyophilization method. A powder is thus obtained, which can be used 15 directly or else mixed in an appropriate solvent before use. An aqueous extract is preferentially used according to the invention. Detailed methods of extract preparation which 20 can be used according to the invention are additionally given in the examples. The quantity of extract of at least one plant of the genus Chrysanthemum contained in the composition of the invention is, of course, a function of the 25 effect sought and of the form of the extract used in the composition. It can therefore vary to a wide extent.
WO 99/13856 - 10 - PCT/FR98/01958 To give an order of size, whatever its nature, the composition can contain an extract of at least one plant of the genus Chrysanthemum in a quantity representing from 0.01% to 15% of the total 5 weight of the composition and preferentially in a quantity representing from 1% to 5% of the total weight of the composition. The compositions according to the invention are essentially intended to increase the pigmentation 10 of the skin and/or of the hair and/or to stimulate melanogenesis. Whatever its nature, the composition of the invention is essentially applied to the skin (on any cutaneous area of the body) and/or the hair. According to the method of administration, 15 the composition according to the invention can be present in any of the pharmaceutical forms normally used. For topical application to the skin, the composition can have the form especially of an aqueous 20 or oily solution or of a dispersion of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (0/W) or conversely (W/o), or of suspensions or emulsions of soft 25 consistency of the aqueous or anhydrous cream or gel type, or alternatively of microcapsules or microparticles, or of vesicular dispersions of ionic k'..A 7 - 0~ WO 99/13856 - 11 - PCT/FR98/01958 and/or non-ionic type. These compositions are prepared according to the usual methods. They can likewise be used for the hair in the form of aqueous, alcoholic or aqueous-alcoholic 5 solutions, or in the form of creams, gels, emulsions, foams or even in the form of aerosol compositions likewise comprising a propellant under pressure. The quantities of the different constituents of the compositions according to the invention are 10 those conventionally used in the fields considered. These compositions especially form cleansing, protection, treatment or care creams for the face, for the hands, for the feet, for the major anatomical folds or for the body (for example day creams, night creams, 15 make-up removal creams, foundation creams, suntan creams), liquid foundations, make-up removal milks, protection or care body milks, suntan milks, lotions, gels or foams for the care of the skin, such as cleansing lotions, suntan lotions, artificial tanning 20 lotions, compositions for the bath, deodorant compositions comprising a bactericidal agent, gels or after-shave lotions, epilatory creams, compositions against insect stings, analgesic compositions, compositions for treating certain diseases of the skin 25 such as eczema, rosacea, psoriasis, lichens and severe pruritus.
WO 99/13856 - 12 - PCT/FR98/01958 The compositions according to the invention can likewise consist of solid preparations forming cleansing soaps or cakes. The compositions can also be packaged in the 5 form of an aerosol composition likewise comprising a propellant under pressure. The composition according to the invention can also be a composition for hair care, and especially a shampoo, hair setting lotion, a treatment lotion, a hair-styling 10 cream or gel, a dye composition (especially oxidation dyes) possibly in the form of dyeing shampoos, restructuring lotions for the hair, a permanent waving composition (especially a composition for permanent waving for the first time), a hair-loss lotion or gel, 15 an antiparasitic shampoo, etc. When the composition is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight with respect to the total weight of the composition. The 20 oils, the waxes, the emulsifiers and the co-emulsifiers used in the composition in emulsion form are selected from those conventionally used in the cosmetic field. The emulsifier and the co-emulsifier are present, in the composition, in a proportion ranging from 0.3% to 25 30% by weight, and preferably from 0.5 to 20% by weight with respect to the total weight of the composition. The emulsion can, in addition, contain lipid vesicles.
WO 99/13856 - 13 - PCT/FR98/01958 When the composition is a solution or an oily gel, the fatty phase can represent more than 90% of the total weight of the composition. In a known manner, the cosmetic composition 5 can likewise contain adjuvants customary in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, bulking agents, filters, odour absorbers and colouring 10 materials. The quantities of these different adjuvants are those conventionally used in the cosmetic field, and, for example, from 0.01% to 10% of the total weight of the composition. These adjuvants, according to their nature, can be introduced into the fatty phase, into 15 the aqueous phase and/or into lipid spherules. Oils or waxes which can be used in the invention and which can be mentioned are mineral oils (liquid paraffin), vegetable oils (liquid fraction of karite butter, sunflower oil), animal oils (perhydrosqualene), 20 synthetic oils (Purcellin oil), siliconized oils or waxes (cyclomethicone) and fluorinated oils (perfluoropolyethers), beeswax, carnauba wax or paraffin wax. It is possible to add to these oils fatty alcohols and fatty acids (stearic acid). 25 Emulsifiers which can be used in the invention and which can be mentioned are, for example, glycerol stearate, polysorbate 60 and the mixture of cTR WO 99/13856 - 14 - PCT/FR98/01958 PEG-6/PEG-32/Glycol Stearate sold under the name of Tefose 63 by Gattefosse. Solvents which can be used in the invention and which can be mentioned are the lower alcohols, 5 especially ethanol and isopropanol, and propylene glycol. Hydrophilic gelling agents which can be used in the invention and which can be mentioned are the carboxyvinyl polymers (carbomer), the acrylic 10 copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural rubbers and clays, and lipophilic gelling agents which can be mentioned are modified clays such as bentonites, metal salts of fatty 15 acids such as aluminium stearates and hydrophobic silica, ethylcellulose and polyethylene. The composition can contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar 20 derivatives, water-soluble vitamins, plant extracts and hydroxyacids. Lipophilic active agents which can be used are retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essentially fatty 25 acids, ceramides, essential oils, salicylic acid and its derivatives. 4-i WO 99/13856 - 15 - PCT/FR98/01958 According to the invention, the composition can comprise other active agents intended especially for the prevention and/or the treatment of cutaneous disorders. Among these active agents, it is possible to 5 mention by way of example: - agents decreasing cutaneous differentiation and/or proliferation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, oestrogens such as oestradiol; 10 - antibacterial agents such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class; - antiparasitic agents, in particular metronidazole, crotamiton or pyrethroids; - antifungal agents, in particular compounds belonging 15 to the imidazoles class such as econazole, ketoconazole or miconazole or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or alternatively octopirox; - antiviral agents such as acyclovir; 20 - steroidal anti-inflammatory agents, such as hydrocortisone, betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or 25 glycyrrhetic acid; - anaesthetic agents such as lidocaine hydrochloride and its derivatives; 4-" WO 99/13856 - 16 - PCT/FR98/01958 - antipruritic agents such as thenaldine, trimeprazine or cyproheptadine; - keratolytic agents such as a- and p-hydroxycarboxylic or P-ketocarboxylic acids, their salts, amides or 5 esters and more particularly hydroxyacids such as glycolic acid, lactic acid, salicylic acid, citric acid and, generally speaking, fruit acids, and n-octanoyl 5-salicylic acid; - anti-free radical agents, such as a-tocopherol or its 10 esters, superoxide dismutases, certain metal chelating agents or ascorbic acid and its esters; - antiseborrheic agents such as progesterone; - antidandruff agents such as octopirox or zinc pyrithione; 15 - antiacne agents such as retinoic acid or benzoyl peroxide; - agents assisting the pigmentation of the skin and/or of the hair such as, for example, the substrates of at least one enzyme having a tyrosinase activity such as, 20 for example tyrosine or its derivatives or 3, 4-dihydroxyphenyl-a-alanine (DOPA), the derivatives of pyrimidine 3-oxide, substituted in the 6 position, such as, for example, those described in the patent application of the applicant filed in France under the 25 number 96-11316 corresponding to the general formula (I) WO 99/13856 - 17 - PCT/FR98/01958 NH N NH R'. N C') .. N R. in which Ri and R 2 , which are identical or different, are a 5 hydrogen atom or a C 1
-C
1 2 alkyl radical;
R
3 and R 4 , which are identical or different, are a C 1
-C
12 alkyl radical, or taken together can form a heterocycle with the nitrogen atom to which they are bonded; it being understood that when R3 and R4 taken together 10 form a piperidino cyclic system then at least one of the radicals Ri or R2 must be different from a hydrogen atom amongst which it is possible to mention particularly: 2-amino-4-propylamino-6-dimethylaminopyrimidine 15 3-oxide, 2 -amino-4-methylamino-6-piperidinopyrimidine 3-oxide, 2, 4 -bis-propylamino-6-dimethylaminopyrimidine 3-oxide, 2, 4 -bis-propylamino-6-piperidinopyrimidine 3-oxide, 2, 4 -bis-methylamino-6-dimethylaminopyrimidine 3-oxide, 20 2, 4 -bis-ethylamino-6-dimethylaminopyrimidine 3-oxide; extracts of bacterial origin such as, for example, extracts of non-photosynthetic filamentous bacteria -1) WO 99/13856 - 18 - PCT/FR98/01958 such as, for example, extracts of Vitreoscilla filiformis. Thus, the composition according to the invention can likewise comprise at least one agent 5 selected from antibacterial, antiparasitic, antifungal, antiviral, anti-inflammatory, antipruritic, anaesthetic, keratolytic, anti-free radical, anti seborrheic, antidandruff and antiacne agents, agents modulating cell differentiation and/or proliferation 10 and/or agents assisting pigmentation of the skin and/or the hair. It is likewise possible to envisage that the composition is in liposomal form, such as especially described in the Patent Application WO 94/22468 filed 15 on 13 October 1994 by the company Anti Cancer Inc. Thus, the compound encapsulated in the liposomes can be delivered selectively at the level of the hair follicle. The invention likewise relates to a cosmetic 20 treatment procedure for increasing the pigmentation of the skin and/or the hair such that a cosmetic composition comprising at least one extract of at least one plant of the genus Chrysanthemum is applied to the skin and/or the hair in a cosmetically acceptable 25 medium.
WO 99/13856 - 19 - PCT/FR98/01958 Cosmetically acceptable medium is understood as meaning a medium compatible with the skin, the mucous membranes, the nails and the hair. It is now intended to give, by way of 5 illustration, examples which are not intended to limit, in any manner, the scope of the invention. Example 1: Preparation of an extract of Chrysanthemum morifolium variety sinense: 10 Leaves of plants of Chrysanthemum morifolium variety sinense cultivated in a greenhouse are taken and dried for 48 hours in a ventilated oven at a temperature of 45*C. The dried leaves are then reduced to powder by grinding 15 in a knife grinder of the Culatti type. The powder obtained is sieved through a grille whose holes have a diameter of 1 mm. It is this sieved powder which is used for the preparation of the extract. 20 Protocol 1: The powder is mixed with an aqueous extraction solvent formed by cell culture medium DMEM/F 12.3:1 sold by the company Life Technologies, at 25 a concentration rate of 5 grams of dry powder per 100 ml of solvent. The mixture is stirred for 4 hours at ambient temperature. The mixture is then centrifuged WO 99/13856 - 20 - PCT/FR98/01958 at 1000 revolutions/minute for 8 minutes and the supernatant is taken and subjected to two identical cycles of centrifugation/sampling. The last supernatant taken is filtered through a 5 0.22 pm filter of the Millipore type under aseptic conditions before being sterilized and kept at a temperature of 4 0 C until use. Protocol 2: 10 The powder is mixed with sterile demineralized water having a pH of 6.5 at a concentration rate of 2.5 grams of dry powder per 100 ml of water. The mixture is stirred for 30 minutes at ambient temperature. The mixture is then filtered 15 through GFD membranes sold by the company Whatmann and having a porosity of 0.7 p. The filtrate obtained is then filtered through a 0.22 pm filter of Nalgene type under aseptic conditions before being sterilized and kept at a temperature of 4 0 C until use. 20 Protocol 3: The previous protocol is carried out replacing the water by an aqueous extraction solvent formed by cell culture medium DMEM/F 12.3:1 sold by the 25 company Life Technologies.
WO 99/13856 - 21 - PCT/FR98/01958 Protocol 4: The extract obtained in Protocol 2 is lyophilized at 30 0 C before freezing at -20 0 C. The powder obtained is used directly. 5 Example 2: Measurement of the modulator effect on the melanogenesis of the extract obtained by Protocol 2 of Example 1: The modulator effect on melanogenesis of the 10 extract obtained by Protocol 2 of Example 1 was tested on co-cultures of normal human keratinocytes/ melanocytes according to the method described in the Patent FR 95 06491. The rate of synthesis of melanine is evaluated by the incorporation of thiouracil 15 labelled with C1 4 . The synthesis of the proteins, determined by the incorporation of tritiated leucine, is taken as an indicator of cytotoxicity and of proliferation. 20 MATERIAL AND METHODS - Cell cultures: The normal human keratinocytes (NHK) and the normal human melanocytes (NHM) are cultured from preputial skin. The two types of cells are proliferated 25 and stored frozen. Eight days before the test, each of the cell types is again put into culture in KGM medium from Gibco for keratinocytes (NHK) and into M2 medium WO 99/13856 - 22 - PCT/FR98/01958 from Dr Olsson for melanocytes (NHM) (Olsson, M.J. et al., Lancet (1992) 340, 981). The media are changed every two days. Forty-eight hours before confluence, the KGM medium of 5 the NHK is replaced by a differentiation medium (DMEM/F 12 3:1, 10% calf serum, 10 ng/ml EGF, 0.4 ptg/ml hydrocortisone, 5 pg/ml insulin). - Plant extract The plant extract of Example 1 (Protocol 2) 10 is tested at the concentrations of 1.25 10-4, 2.5 10-4, 5 10~4, 1.25 10-', 2.5 10~, 5 10~ %. - Modulation of melanogenesis 250,000 normal human keratinocytes and 80,000 normal human melanocytes are mixed and sown in wells of 15 24-well plates (Costar type) and cultured for three days in the differentiation medium. During the three following days, the culture medium is replaced daily by the defined test medium (DMEM/F 12 3:1, 10 ng/ml epidermal growth factor (EGF), 10 ng/ml fibroblastic 20 growth factor of type f (pFGF)) containing 1 pCi/ml of thiouracil labelled with C14. The following controls are carried out: - culture control: no product to be tested; - positive control of stimulation of melanogenesis: 25 1 mM tyrosine; - positive control of inhibition of melanogenesis: 0.5 mM kojic acid.
WO 99/13856 - 23 - PCT/FR98/01958 The total radioactivity incorporated in the proteins is estimated by the incorporation of tritiated leucine. The day before taking, 1 pCi/ml of tritiated leucine is added to the test medium. 5 After one night, the cells are rinsed in phosphate buffer. The proteins are precipitated with the aid of 5% trichloroacetic acid (TCA) and washed in order to eliminate the free radioactivity. The proteins are incubated overnight at 40 0 C with the aid of a 100 pg/ml 10 proteinase K solution in a tris HCl-triton-EDTA buffer. 50 pl of total extract are taken and transferred into a 24-well plate (Wallac) and 500 pl of scintillation fluid (Optiphase "Supermix") are added. The remainder of the extract, or 950 pl, is filtered 15 through a DEAE Filtermat filter. After rinsing, the "Meltilex" filter covered with the solid scintillant is transferred onto a plate. The radioactivity is counted with the aid of the Wallac counter. The results are expressed as a percentage of the control according to 20 the formula: (14CP I 3HP) - (14CT / 3HT) X 100 (14CT 3HT) in which: WO 99/13856 - 24 - PCT/FR98/01958 14CP is the average of the disintegrations per minute (dpm) of 1 4 C thiouracil in 3 similar wells treated with a product (P); 3 HP is the average of the corresponding 3H leucine dpm; 5 14CT is the average of the 14C thiouracil dpm in 3 similar control wells (T); 3 HT is the average of the corresponding 3 H leucine dpm. RESULTS: Products 3 HLeu. (%/control) 14 CThioU. (%/control) 1 mM tyrosine -2 +118 5 10~4% extract -1 +92 2.5 10-3% extract +5 +502 5 10-3% extract -13 +932 0.5 mM kojic acid +4 -47 10 CONCLUSIONS: This product is non-cytotoxic at the concentrations tested (non-significant variation of the incorporation of 3 HLeu.) and induces the synthesis of 15 melanine from 1.25 10-3% (increase in the incorporation of 14 CThioU. \((7A WO 99/13856 - 25 - PCT/FR98/01958 Example 3: Examples of compositions containing at least one extract of at least one plant of the genus Chrysanthemum. These compositions are obtained by the 5 customary techniques currently used in cosmetics or in pharmacy. Dermal cream: Extract of Example 1, Protocol 1 5.000 g Ceteareth 30 7.000 g Glyceryl stearate 2.000 g Cetyl alcohol 1.500 g Polydimethylsiloxane 1.500 g Paraffin oil 15.000 g Glycerol codex pure 20.000 g Preservatives q.s. Demineralized water q.s. 100.000 g Dermal lotion for spraying: Extract of Example 1, Protocol 2 10.000 g 3,4-Dihydroxyphenyl-a-alanine (DOPA) 0.200 g Ethanol 30.000 g Demineralized water q.s. 100.000 g Lotion for the hair: Extract of Example 1, Protocol 4 0.500 g Tyrosine 1.000 g Propylene glycol 30.000 g Ethyl alcohol 40.500 g Water qs. 100.000 g WO 99/13856 - 26 - PCT/FR98/01958 This lotion is applied to the scalp, one to two times per day, at a rate of 1 ml per application. Thickened lotion: Extract of Example 1, Protocol 3 15.000 g Kawaine 2.000 g Hydroxypropylcellulose (Klucel G® from Hercules) 3.500 g Ethyl alcohol qsp 100.000 g 5 This thickened lotion is applied to the scalp, one to two times per day, at a rate of 1 ml per application. Niosomal lotion: Extract of Example 1, Protocol 1 1.000 g Chimexane NL* 0.475 g Cholesterol 0.475 g Monosodium stearoylglutamate 0.050 g Preservatives qs Colorants qs Perfume qs Demineralized water qs 100.000 g 10 This lotion is applied to the scalp, one to two times per day, at a rate of 1 ml per application.
WO 99/13856 - 27 - PCT/FR98/01958 Lotion: Extract of Example 1, Protocol 2 2.000 g Tyrosine 1.000 g Propylene glycol monomethyl ether (Dowanol PM from Dow Chemical) 20.000 g Hydro Ethyl alcohol 40.000 g Minoxidil 2.000 g Water qs 100.000 g This thickened lotion is applied to the scalp, one to two times per day, at a rate of 1 ml per 5 application.
Claims (10)
1. Use, as active principle, in a cosmetic composition or for the preparation of a pharmaceutical composition, of a sufficient quantity of at least one 5 extract of at least one plant of the genus Chrysanthemum, this extract or the composition being intended to increase the pigmentation of the skin and/or the hair.
2. Use, as active principle, in a cosmetic 10 composition or for the preparation of a pharmaceutical composition, of a sufficient quantity of at least one extract of at least one plant of the genus Chrysanthemum to stimulate melanogenesis.
3. Use according to any one of the 15 preceding claims, characterized by the fact that the said plant is selected from the species Chrysanthemum hortorum, Chrysanthemum morifolium, Chrysanthemum coronarium, Chrysanthemum myconis, Chrysanthemum sagitum, Chrysanthemum indicum, or alternatively 20 Chrysanthemum segetum.
4. Use according to the preceding claim, characterized by the fact that the said plant comes from the species Chrysanthemum morifolium.
5. Use according to Claim 4, characterized 25 by the fact that the said plant comes from the variety sinense. WO 99/13856 - 29 - PCT/FR98/01958
6. Use according to any one of the preceding claims, characterized by the fact that the extract of at least one plant of the genus Chrysanthemum is obtained from plant material 5 originating from the entire plant cultivated in vivo or originating from in vitro culture.
7. Use according to any one of the preceding claims, characterized by the fact that the extract of at least one plant of the genus 10 Chrysanthemum is obtained from leaves, flowers, stems, roots or undifferentiated cells.
8. Use according to any one of the preceding claims, characterized by the fact that the extract of at least one plant of the genus 15 Chrysanthemum is in a quantity representing from 0.01% to 15% of the total weight of the composition and preferentially in a quantity representing from 1% to 5% of the total weight of the composition.
9. Cosmetic or pharmaceutical composition 20 comprising at least one extract of at least one plant of the genus Chrysanthemum such as defined in one of Claims 1 to 8 and at least one agent selected from antibacterial, antiparasitic, antifungal, antiviral, anti-inflammatory, antipruritic, anaesthetic, 25 keratolytic, anti-free radical, anti-seborrheic, antidandruff and antiacne agents, agents modulating WO 99/13856 - 30 - PCT/FR98/019 5 8 cell differentiation and/or proliferation and/or agents assisting pigmentation of the skin and/or the hair.
10. Cosmetic treatment procedure for increasing the pigmentation of the skin and/or the 5 hair, characterized by the fact that a cosmetic composition comprising at least one extract of at least one plant of the genus Chrysanthemum is applied to the skin and/or the hair in a cosmetically acceptable medium.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/11648 | 1997-09-18 | ||
FR9711648A FR2768343B1 (en) | 1997-09-18 | 1997-09-18 | USE OF AT LEAST ONE EXTRACT OF AT LEAST ONE PLANT OF THE GENUS CHRYSANTHEMUM FOR PROMOTING PIGMENTATION OF THE SKIN AND / OR HAIR |
PCT/FR1998/001958 WO1999013856A1 (en) | 1997-09-18 | 1998-09-14 | Use of at least an extract of the genus chrysanthemum for stimulating skin and/or hair pigmentation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU9167798A true AU9167798A (en) | 1999-04-05 |
AU739954B2 AU739954B2 (en) | 2001-10-25 |
Family
ID=9511234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU91677/98A Ceased AU739954B2 (en) | 1997-09-18 | 1998-09-14 | Use of at least an extract of the genus chrysanthemum for assisting skin and/or hair pigmentation |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1014934B1 (en) |
JP (1) | JP3615705B2 (en) |
CN (1) | CN1270513A (en) |
AT (1) | ATE211905T1 (en) |
AU (1) | AU739954B2 (en) |
BR (1) | BR9814937A (en) |
CA (1) | CA2303141A1 (en) |
DE (1) | DE69803200T2 (en) |
DK (1) | DK1014934T3 (en) |
ES (1) | ES2172194T3 (en) |
FR (1) | FR2768343B1 (en) |
HU (1) | HUP0004420A3 (en) |
PL (1) | PL339663A1 (en) |
PT (1) | PT1014934E (en) |
RU (1) | RU2197945C2 (en) |
WO (1) | WO1999013856A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2823112B1 (en) * | 2001-04-09 | 2004-03-05 | Oreal | TANNING AND FILTERING PRODUCT |
DE10160966A1 (en) * | 2001-12-12 | 2003-06-26 | Beiersdorf Ag | Melanin-forming hair coloring product |
FR2831439A1 (en) * | 2002-02-14 | 2003-05-02 | Oreal | Cosmetic composition used for coloring or repigmenting skin or hair contains self tanning agent and melanogenesis activator |
FR2831438A1 (en) * | 2002-02-14 | 2003-05-02 | Oreal | New cosmetic or dermatological composition useful for activating melanogenesis to color or repigment skin or hair |
FR2831445A1 (en) * | 2002-02-14 | 2003-05-02 | Oreal | Cosmetic composition contains skin peeling agent to maximize effects of compounds that induce skin pigmentation by acting on melanin biosynthesis |
KR20030086849A (en) * | 2002-05-07 | 2003-11-12 | 메디코룩스(주) | A composition for whitening containing crown daisy extract |
JP4880233B2 (en) * | 2004-03-17 | 2012-02-22 | 株式会社コーセー | Anti-dermatological agent and external preparation for skin containing the same |
FR2865132A1 (en) * | 2004-07-06 | 2005-07-22 | Oreal | Use of diosmetin and its derivatives for cosmetic or therapeutic pigmentation of skin and hair, e.g. for treating vitiligo, acts by stimulating melanogenesis |
KR100802192B1 (en) * | 2004-07-27 | 2008-02-11 | 이병수 | Hair Growth Component Using Herbs |
JP2007197352A (en) * | 2006-01-25 | 2007-08-09 | Kameda Seika Co Ltd | Melanin production promoter |
FR2904540B1 (en) * | 2006-08-03 | 2011-05-06 | Soc Extraction Principes Actif | USE OF SUNFLOWER EXTRACT AS ACTIVE AGENT FOR INCREASING THE SYNTHESIS OF MELANIN IN MELANOCYTES |
WO2008015342A2 (en) * | 2006-08-03 | 2008-02-07 | Societe D'extraction Des Principes Actifs Sa (Vincience) | Use of a plant extract as active agent for increasing melanin synthesis in melanocytes |
FR2930647B1 (en) * | 2008-04-25 | 2015-05-22 | Oreal | METHOD FOR IDENTIFYING A COMPOUND MODULATING THE PIGMENTATION OF HUMAN FOLLICLE FOLLICLES AND / OR PROTECTING HUMAN FOLLICLE MELANOCYTES |
FR2951938B1 (en) | 2009-10-30 | 2012-01-06 | Oreal | USE OF A PUNICA GRANATUM EXTRACT TO COMBAT CANITIS |
CN103783091B (en) * | 2012-10-31 | 2018-05-29 | 浙江农林大学 | Mother chrysanthemum polysaccharide is in the application agriculturally as disease-resistant elicitor |
CN103621620A (en) * | 2013-12-04 | 2014-03-12 | 河北省林业科学研究院 | Application of artemisia extractive as fruit coloring accelerant |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58135803A (en) * | 1982-02-05 | 1983-08-12 | Noriko Sugano | Preparation of nutrient beauty lotion |
JPS6248611A (en) * | 1985-08-28 | 1987-03-03 | Shiseido Co Ltd | External preparation for skin |
US4911925A (en) * | 1989-04-17 | 1990-03-27 | Lima Shatkina | Vegetable extracts for skin treatment |
CN1094278A (en) * | 1993-04-22 | 1994-11-02 | 王能强 | Pure natural medicine type physical therapy health care hair care fixing foaming agent |
CN1054748C (en) * | 1994-05-10 | 2000-07-26 | 刘侠 | Medicine for acne |
-
1997
- 1997-09-18 FR FR9711648A patent/FR2768343B1/en not_active Expired - Fee Related
-
1998
- 1998-09-14 PL PL98339663A patent/PL339663A1/en unknown
- 1998-09-14 RU RU2000109566/14A patent/RU2197945C2/en not_active IP Right Cessation
- 1998-09-14 JP JP2000511481A patent/JP3615705B2/en not_active Expired - Fee Related
- 1998-09-14 BR BR9814937-7A patent/BR9814937A/en not_active IP Right Cessation
- 1998-09-14 DK DK98943977T patent/DK1014934T3/en active
- 1998-09-14 CN CN98809300A patent/CN1270513A/en active Pending
- 1998-09-14 AT AT98943977T patent/ATE211905T1/en not_active IP Right Cessation
- 1998-09-14 CA CA002303141A patent/CA2303141A1/en not_active Abandoned
- 1998-09-14 HU HU0004420A patent/HUP0004420A3/en unknown
- 1998-09-14 AU AU91677/98A patent/AU739954B2/en not_active Ceased
- 1998-09-14 ES ES98943977T patent/ES2172194T3/en not_active Expired - Lifetime
- 1998-09-14 DE DE69803200T patent/DE69803200T2/en not_active Expired - Lifetime
- 1998-09-14 PT PT98943977T patent/PT1014934E/en unknown
- 1998-09-14 EP EP98943977A patent/EP1014934B1/en not_active Expired - Lifetime
- 1998-09-14 WO PCT/FR1998/001958 patent/WO1999013856A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO1999013856A1 (en) | 1999-03-25 |
FR2768343A1 (en) | 1999-03-19 |
EP1014934B1 (en) | 2002-01-16 |
ATE211905T1 (en) | 2002-02-15 |
CN1270513A (en) | 2000-10-18 |
AU739954B2 (en) | 2001-10-25 |
EP1014934A1 (en) | 2000-07-05 |
PL339663A1 (en) | 2001-01-02 |
DE69803200D1 (en) | 2002-02-21 |
FR2768343B1 (en) | 2000-03-10 |
DE69803200T2 (en) | 2002-10-31 |
ES2172194T3 (en) | 2002-09-16 |
HUP0004420A2 (en) | 2001-05-28 |
DK1014934T3 (en) | 2002-05-06 |
JP2001516710A (en) | 2001-10-02 |
RU2197945C2 (en) | 2003-02-10 |
JP3615705B2 (en) | 2005-02-02 |
CA2303141A1 (en) | 1999-03-25 |
HUP0004420A3 (en) | 2003-12-29 |
BR9814937A (en) | 2000-10-17 |
PT1014934E (en) | 2002-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4974532B2 (en) | Use of at least one cypress plant extract as an anti-glycation agent | |
AU739954B2 (en) | Use of at least an extract of the genus chrysanthemum for assisting skin and/or hair pigmentation | |
US6060061A (en) | Method for preventing or treating disorders involving an inflammatory process | |
CA1300511C (en) | Cosmetic composition containing a hair growth promoter | |
US20090010976A1 (en) | Cosmetic or dermopharmaceutical compositions containing kombucha | |
KR20200026646A (en) | Cosmetic Composition for Improving Skin Condition Comprising Plant cell complex cultures to improve skin radiance and vitality | |
US20050281900A1 (en) | Plant extract of the species Vitis vinifera as no-synthase inhibitor and uses | |
US20100179200A1 (en) | 2-oxothiazolidine 4-carboxylic acid compounds for promoting desquamation of the skin | |
KR101998032B1 (en) | Cosmetic Composition for Improving Skin Condition Comprising Rosa Damascena Callus Culture Extract or the fermented filtrates to improve periorbital wrinkles, skin brightness and calm troubled skin | |
US7192616B2 (en) | Plant extract of the Olea europaea species as NO-synthase inhibitor and uses | |
US6187325B1 (en) | Use of at least one extract of a rosacea of the genus Sanguisorba officinalis for promoting pigmentation of the skin and/or the body hair and/or the cranial hair | |
AU700465B2 (en) | Use in a composition as tyrosinase stimulator, of at least one pyrimidine 3-oxide derivative, substituted in position 6 | |
KR20200014570A (en) | Cosmetic Composition for Improving Skin Condition Comprising Passiflora alata to improve skin radiance and vitality | |
JP2883835B2 (en) | Extract from Catharanthus roseus seed, method for obtaining the same, and composition containing the same | |
KR102016062B1 (en) | Callus extracts from Citrus junos Siebold ex Tanaka and Pyrus pyrifolia Nakai with Whitening and Anti-wrinkle effect | |
US6726940B2 (en) | Use of at least one extract of the genus chrysanthemum for assisting skin and/or hair pigmentation | |
KR20210060801A (en) | Cosmetic Compositions for Anti-aging Comprising Complex Fermented Product of Plants | |
KR100794518B1 (en) | A cosmetic composition containing a extract of Viola tricolor L. | |
JP2000510165A (en) | Combination of Phenol Derivatives with Iridaceae Extract for Depigmentation of Skin and Body Growth and Compositions Containing It | |
US20020041908A1 (en) | Iridacea extracts for stimulating the immune system | |
MXPA00002328A (en) | Use of at least an extract of the genus chrysanthemum for stimulating skin and/or hair pigmentation | |
KR100702176B1 (en) | Low stimulative cosmetic composition | |
US20020041907A1 (en) | Sophora japonica extracts for promoting desquamation/epidermal renewal of the skin and/or combating skin aging | |
US20040071798A1 (en) | Admixture of extracts of plants of the genus rosmarinus and carotenoids for treating cutaneous symptoms of aging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |